1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Tibet Aim Pharm., Inc. Class A

Tibet Aim Pharm., Inc. Class A

SSZSE:002826
15.86
CNY
+0.05
(+0.32%)
0.52EPS
28.90P/E
2.87BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.17
2.16
2.57
3.1
2.01
2.52
2.96
3.23
3.76
4.46
3.47
3.55
3.44
3.62
Basic EPS, GAAP
0.1
0.24
0.37
0.38
0.32
0.13
0.2
0.22
0.22
0.23
0.08
0.25
0.5
0.52
Free Cash Flow per Basic Share
0.12
-0.32
-0.55
0.27
0.01
-0.28
-0.6
0.34
0.44
0.34
0.85
0.54
0.62
- -
Dividend per Share
0.01
0.02
0.01
0.02
0.06
0.07
0.05
0.05
0.08
0.1
0.11
0.03
0.13
0.26
Book Value per Share
1.3
1.33
1.74
2.93
3.19
3.26
3.38
3.58
3.75
3.91
3.91
3.88
4.28
4.53
Tangible Book Value per Share
0.85
1.1
1.42
2.68
2.92
2.98
3.09
3.32
3.37
3.55
3.68
3.68
4.09
4.34
Basic Weighted Avg Shares
190
135
135
146
189
194
187
187
193
192
192
184
185
185
Sales/Revenue/Turnover
221
291
347
452
380
489
553
603
725
857
667
652
636
670
Operating Margin (%)
5.56
11.13
13.81
12.63
17.4
5.12
8.57
7.48
5.87
6.56
4.69
8.91
15.5
17.95
Depreciation Expense
3
3
3
7
8
9
11
17
24
23
24
22
19
- -
Net Income, GAAP
20
32
50
55
60
25
37
41
42
44
15
46
93
96
Effective Tax Rate (%)
16.69
20.4
10.85
12.4
10.96
12.89
21.8
13.22
13.08
18.67
33.36
21.39
18.08
21.02
Profit Margin (%)
8.91
11.14
14.42
12.25
15.9
5.17
6.75
6.82
5.86
5.15
2.31
7.05
14.55
14.37
Working Capital
-3
71
101
363
353
327
220
232
263
313
319
352
437
462
LT Debt
- -
- -
40
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
72
179
248
555
605
618
652
687
720
750
750
746
816
864
Return on Invested Capital (%)
- -
16.41
15.9
9.34
9.82
3.66
5.37
5.09
5.75
5.91
1.99
6.29
10.24
11.38
Return on Capital (%)
- -
22.84
20.42
13.36
10.42
4.19
5.71
5.86
5.83
5.63
2.03
5.85
11.64
11.41
Return on Common Equity (%)
- -
26.52
23.41
13.78
10.43
4.13
5.88
6.14
6.05
6.03
2.06
6.19
11.91
11.85

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
- -
29
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
191
191
191
Market Capitalization
3,505
3,804
2,866

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
634
723
791
Cash, Cash Equivalents & STI
538
634
699
Accounts Receivable, Net
13
22
20
Inventories
60
57
54
Total Current Liabilities
197
260
328
Payables & Accruals
- -
- -
- -
ST Debt
11
- -
29
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.35%
3.56%
9.45%
Free Cash Flow
-229.55%
27.62%
16%
Net Income, GAAP
26.18%
48.44%
101.57%
Sales/Revenue/Turnover
7.67%
2.34%
-2.39%
Total Cash Common Dividend
90.45%
64.7%
294.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
160
192
161
139
652
2025
149
163
- -
147
636
2026
183
177
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.06
0.01
0.02
0.25
2025
0.1
0.1
- -
0.06
0.5
2026
0.11
0.25
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
- -
- -
0.03
2025
- -
0.1
- -
- -
0.13
2026
- -
0.15
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ke Xu
Full Time Employees
405
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 6, Linqionggang Road Chengdu China 850000
IPO Date
Dec 9, 2016
Website
emyy.cn
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Tibet AIM Pharm Inc (002826.SZ) engages primarily in the research, development, manufacturing, and sale of pharmaceutical products in China, with a focus on treatments for chronic diseases including diabetes and cardiovascular conditions; gynecology and obstetrics medications; antibiotics; antiallergic drugs; and digestive system therapies. Core products encompass Miglitol Tablets for diabetes management; Gualoupi Injection for coronary disease; Nalmefene Hydrochloride Injection for acute poisoning, shock, and cerebral conditions; Carbetocin Injection for postpartum hemorrhage prevention; Hongjin Xiaojie Tablets and Aceclofenac Enteric-Coated Tablets for pain and inflammation; Domperidone Tablets for gastrointestinal disorders; Montmorillonite Powder for chronic diarrhea; Azithromycin Capsules; Loratadine Tablets; and various multivitamin and trace element injections, many of which are included in China's National Medical Insurance catalog and supported by domestic patents for generic drugs. Founded in 2003 and listed on the Shenzhen Stock Exchange since December 2016, the company is headquartered in the Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, with subsidiaries including Aim Kangyuan Pharmaceuticals Technology Co and Aim Haizhong Investment and Management Co in Beijing; Wei’Ao Pharmaceuticals Ltd in Sichuan; manufacturing facilities in Lhasa, Tibet, and Pengzhou, Sichuan; and an herbal planting base in Linzhi, Tibet, serving customers nationwide through integrated production, active pharmaceutical ingredient supply, and drug promotion services. In June 2025, Fuhao Enterprise Management, controlled by 58.com founder Yao Jinbo, acquired a 23% stake for CNY662 million from former chairman Gao Fan, positioning it as the largest shareholder and committing the company to minimum annual net profits of CNY30 million and revenue of CNY600 million through 2027; this follows a 2024 strategic shift reducing third-party partnerships amid centralized procurement pressures, which tripled net profit to CNY45.9 million on CNY652 million revenue despite a slight sales decline.